The Food and Drug Administration (FDA) has recently approved Viibryd (vilazodone hydrochloride) to treat adults suffering from major depressive disorder.
As we usually do here at Health Care Zone, we’d like to focus on the side effects of this newly approved drug and this is what the FDA says about the matter:
The most frequent adverse reactions reported by patients taking Viibryd in clinical trials included diarrhea, nausea, vomiting, and insomnia.
Viibryd and all other antidepressant drugs have a boxed warning and a patient medication guide describing the increased risk of suicidal thinking and behavior in children, adolescents, and young adults ages 18 to 24 during initial treatment.
Viibryd, manufactured by PGxHealth in New Haven, Connecticut, will be made available in 10, 20 and 40 milligram tablets.
An advantage of Viibryd over other anti-depression drugs is that it reportedly does not reduce one’s sexual desire. Nice, no? Who says you have to give up sex while getting rid of your depression – they’re not mutually exclusive after all.
Another advantage? Unlike other drugs, Viibryd reportedly does not result in weight gain. Reuters reports:
In clinical trials, vilazodone use did not cause significant weight gain or the negative impact on sexual desire or function seen with many other antidepressants that lead many patients to abandon their medicine.
UPDATE: 09 September 2011
Viibryd and Weight Gain: One of the most often googled questions asked by our visitors is whether Viibryd causes weight gain.
According to the Daily Med, an information source maintained by the U.S. National Library of Medicine which is operated by the National Institutes of Health, weight gain is not among the adverse side effects noted when the drug was placed under a placebo controlled study. From Daily Med:
VIIBRYD had no effect on body weight as measured by the mean change from baseline in the 8-week, placebo-controlled studies. The mean changes in weight were +0.16 kg in the VIIBRYD group and +0.18 kg in the placebo group. The proportions of patients with a weight gain ≥ 7% were 0.9% in the VIIBRYD group and 1.2% in the placebo group. The proportions of patients with a weight decrease ≥ 7% were 1.4% in the VIIBRYD group and 1.4% in the placebo group.
Serious Side Effects: Having said that, Viibryd does have other side effects we should be aware of. We mentioned in our earlier post that the drug’s most common adverse effects are diarrhea, nausea, vomiting, and insomnia. Moreover, like other anti-depressant medicines, Viibryd may cause serious side effects which the FDA lists as follows: